Immunogenicity and Safety of ZOSTAVAX® Approaching Expiry Potency in Individuals Aged ≥50 Years

Human Vaccines
doi 10.4161/hv.7.10.16480
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

Clinical and Vaccine Immunology
MedicineImmunologyAllergyClinical BiochemistryMicrobiology
2007English

164: Perinatal Outcome of Women Aged 50 Years and Above

American Journal of Obstetrics and Gynecology
GynecologyObstetrics
2019English

Evaluation of the Reactogenicity, Safety and Immunogenicity of the Domestic Influenza Inactivated Split FLU-M Vaccine in Immunization Adults Aged 18–60 Years

Epidemiology and Vaccine Prevention
2018English

Psy196 - The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Seropersistence of Tick-Borne Encephalitis Antibodies, Safety and Booster Response to FSME-IMMUN®0.5 Ml in Adults Aged 18-67 Years

Human Vaccines
2009English

Characteristics of Abdominal Aortic Aneurysm in Japanese Patients Aged 50 Years or Younger

Annals of Vascular Diseases
2017English

Bone Mineral Density Among Men and Women Aged 35 to 50 Years

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
2019English

Epidemiology of Low-Energy Lower Extremity Fracture in Chinese Populations Aged 50 Years and Above

PLoS ONE
Multidisciplinary
2019English

Clinical, Mammographic and Histopathological Correlation of Breast Cancer in Women Aged Between 50 and 70 Years

Revista Brasileira de Mastologia
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy